Answers are grounded in this paper and cite their sources.
Double-blinded randomized trial shows comparable efficacy of SHT-ME and DF-ME in knee osteoarthritis, suggesting safe alternatives.
Sahasthara (SHT), a traditional Thai herbal remedy used for anti-inflammatory and musculoskeletal disorders, lacks clinical evaluation as a topical formulation employing microemulsion (ME) technology. This study aimed to assess the efficacy and safety of a Sahasthara microemulsion (SHT-ME) compared with a diclofenac microemulsion (DF-ME) in patients with primary knee osteoarthritis (OA). Eighty-four patients aged 40–70 years were randomized to receive either 1% SHT-ME or 2% DF-ME, applied three times daily for 28 days. Efficacy was evaluated using pain visual analogue scale (VAS), 100-meter walking time, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, and global assessments. Safety assessments included physical examinations, laboratory tests, and adverse-event monitoring. Both formulations significantly reduced VAS pain scores, improved walking time, and decreased WOMAC scores at days 14 and 28 compared with baseline (P < 0.05). No significant efficacy differences were observed between groups (P > 0.05). Liver and renal function, blood pressure, and biochemical parameters remained within normal ranges, and no severe or skin-related adverse events occurred in either group. SHT-ME provided efficacy comparable to DF-ME in relieving pain and improving mobility in knee OA. Both treatments were well tolerated and safe. These findings suggest that SHT-ME, a natural herbal alternative, and DF-ME, a synthetic drug formulation, are equally effective topical microemulsions for knee osteoarthritis management. NCT06184685 ( ClinicalTrials.gov ) • This is the first clinical study comparing topical SHT-ME, an essential Thai herbal anti-inflammatory drug, and DF-ME in OA knee patients. • SHT-ME was developed from an oral medication due to its side effects that can cause stomach discomfort or dry mouth. • 1%SHT-ME provides localized drug delivery with the same efficacy as 2%DF-ME in the treatment of OA knee. • Both treatments showed no serious adverse effects both symptomatically and in laboratory studies. • SHT-ME was more effective compared with the oral dose, which used only 60 mg/day or 5 times less than the oral administration.
No takes yet. Share an insight, caveat, or question.
Intharit et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: